Comparative Pharmacology
Head-to-head clinical analysis: HYDASE versus VITRASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDASE versus VITRASE.
HYDASE vs VITRASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYDASE (hyaluronidase) hydrolyzes hyaluronic acid, a glycosaminoglycan in the extracellular matrix, thereby increasing tissue permeability and facilitating the dispersion and absorption of injected fluids or drugs.
VITRASE (hyaluronidase) hydrolyzes hyaluronic acid, a component of the extracellular matrix, thereby increasing tissue permeability to fluids and facilitating the absorption and dispersion of injected drugs.
Intravenous, intramuscular, or subcutaneous: 150-300 units (0.5-1 mL) as a single dose or divided into multiple doses to facilitate hydration and dispersion of other injected drugs. Frequency: as needed based on clinical indication, up to every 2-3 days.
Intravenous administration of 150 units as a bolus injection prior to subcutaneous fluid or medication administration to increase absorption and dispersion.
None Documented
None Documented
2 to 5 minutes intravenously; rapidly inactivated by proteases in plasma and tissues, resulting in ultra-short duration.
Approximately 24 hours for the enzymatic activity; clinical effect persists beyond half-life due to drug action.
Primarily renal; <1% excreted unchanged in urine; extensive metabolism via proteolysis to amino acids and peptides.
Renal: <10% unchanged; remainder metabolized locally.
Category C
Category C
Enzyme
Enzyme